Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Metagenomi, Inc. Common Stock (MGX)
USD1.29
-0.03 (-2.27%)
US NASDAQ Healthcare Biotechnology
Address
5959 Horton Street 94608
Emeryville, US
Emeryville, US
CEO
Jian Irish
Website
metagenomi.co
IPO
2006-04-06
CIK 1785279 ISIN US59102M1045
Description
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.29
-0.03 (-2.27%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
166.7K
Beta
0.65
Float Shares
27.33M
Free Float %
72.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.26% | -3.57% | -2.17% | -6.90% | -27.42% | -16.67% | -12.90% | -86.91% | -86.91% | -86.91% | -86.91% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
1.29
Low
7.00
+442.6%
Consensus
14.50
+1,024.0%
Median
14.50
+1,024.0%
High
22.00
+1,605.4%
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
14.50
+1,024.0%
|
Quality scores
Altman Z-Score
-2.52
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-51.8% Q1'26: -69.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-12.9% Q1'26: +10.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-449.5% Q1'26: -1,698.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-380.9% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-249.7% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.5% ★ Q1'26: +1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.45× Q1'26: -0.40× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
44.76M
est: 47.26M (-5.3%)
|
52.30M
est: 51.81M (+0.9%)
|
25.21M
est: 28.63M (-11.9%)
|
14.81M
13.49M – 16.13M
-48.3% YoY
|
15.19M
14.92M – 15.45M
+2.5% YoY
|
20.00M
16.12M – 29.98M
+31.7% YoY
|
20.00M
16.12M – 29.98M
+0.0% YoY
|
20.00M
16.12M – 29.98M
+0.0% YoY
|
| EBITDA |
-74.29M
est: -47.26M (-57.2%)
|
-83.49M
est: -51.81M (-61.2%)
|
-90.70M
est: -28.63M (-216.8%)
|
-14.81M
-16.13M – -13.49M
+48.3% YoY
|
-15.19M
-15.45M – -14.92M
-2.5% YoY
|
-20.00M
-29.98M – -16.12M
-31.7% YoY
|
-20.00M
-29.98M – -16.12M
+0.0% YoY
|
-20.00M
-29.98M – -16.12M
+0.0% YoY
|
| EBIT |
-78.49M
est: -47.26M (-66.1%)
|
-88.90M
est: -51.81M (-71.6%)
|
-96.01M
est: -28.63M (-235.4%)
|
-14.81M
-16.13M – -13.49M
+48.3% YoY
|
-15.19M
-15.45M – -14.92M
-2.5% YoY
|
-20.00M
-29.98M – -16.12M
-31.7% YoY
|
-20.00M
-29.98M – -16.12M
+0.0% YoY
|
-20.00M
-29.98M – -16.12M
+0.0% YoY
|
| Net Income |
-68.26M
est: -440.12M (+84.5%)
|
-78.06M
est: -90.46M (+13.7%)
|
-87.87M
est: -87.87M (+0.0%)
|
-82.42M
-87.39M – -77.46M
+6.2% YoY
|
-60.41M
-83.67M – -37.14M
+26.7% YoY
|
-81.10M
-99.74M – -62.47M
-34.3% YoY
|
-72.64M
-119.78M – -54.33M
+10.4% YoY
|
-67.05M
-110.56M – -50.15M
+7.7% YoY
|
| SGA |
28.85M
est: 409.95M (-93.0%)
|
32.02M
est: 449.43M (-92.9%)
|
26.79M
est: 248.33M (-89.2%)
|
128.48M
117.03M – 139.93M
-48.3% YoY
|
131.73M
129.42M – 134.05M
+2.5% YoY
|
173.50M
139.86M – 260.10M
+31.7% YoY
|
173.50M
139.86M – 260.10M
+0.0% YoY
|
173.50M
139.86M – 260.10M
+0.0% YoY
|
| EPS |
-1.82
est: -9.86 (+81.5%)
|
-2.09
est: -2.48 (+15.7%)
|
-2.36
est: -2.36 (0.0%)
|
-2.20
-2.35 – -2.08
+6.9% YoY
|
-1.68
-2.25 – -1.00
+23.7% YoY
|
-2.18
-2.68 – -1.68
-29.9% YoY
|
-1.95
-3.22 – -1.46
+10.4% YoY
|
-1.80
-2.97 – -1.35
+7.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-124.46M
OE per share TTM
-3.32
Owner's Yield
-245.31%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
161.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
13
Total invested
2.61M
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bayer Aktiengesellschaft | 4.05M | 10.80% | — | — | — | 4.05M | HC, CO | Citizenship or Place of Organization | 2024-11-06 | ↗ |
| 2 | Bayer HealthCare LLC | 4.05M | 10.80% | — | — | — | 4.05M | CO | Citizenship or Place of Organization | 2024-11-06 | ↗ |
| 3 | Bayer US Holding LP | 4.05M | 10.80% | — | — | — | 4.05M | PN | Citizenship or Place of Organization | 2024-11-06 | ↗ |
| 4 | Bayer World Investments B.V. | 4.05M | 10.80% | — | — | — | 4.05M | CO | Citizenship or Place of Organization | 2024-11-06 | ↗ |
| 5 | S | 600.5K | 1.60% | 600.5K | 600.5K | 600.5K | 600.5K | PN | Cayman Islands | 2024-05-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
13
-41 vs prev Q
New positions
3
Closed positions
44
Increased
5
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 12.5K +12.5K (+100.0%) | 20.25M +20.3M (+100.0%) | 0.03% +0.034 pp | 0.01% +0.006 pp | USD1.62 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 1.27M +28.7K (+2.3%) | 2.06M -884.6K (-30.1%) | 3.40% +0.060 pp | 0.00% +0.000 pp | USD4.02 -59.7% | 8 qtrs — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 628.4K +461.4K (+276.3%) | 1.02M +622.2K (+157.2%) | 1.68% +1.233 pp | 0.00% +0.001 pp | USD1.76 -8.0% | 6 qtrs — |
| 4 | CATALIO CAPITAL MANAGEMENT, LP | 529.0K +— (+0.0%) | 857.0K -396.7K (-31.6%) | 1.42% -0.007 pp | 0.15% -0.080 pp | USD3.61 -55.1% | 5 qtrs — |
| 5 | PEAPOD LANE CAPITAL LLC | 497.7K -16.2K (-3.1%) | 806.2K -412.2K (-33.8%) | 1.33% -0.050 pp | 0.69% -0.404 pp | USD2.95 -45.1% | 5 qtrs — |
| 6 | TWO SIGMA INVESTMENTS, LP | 441.4K +233.9K (+112.7%) | 715.0K +223.2K (+45.4%) | 1.18% +0.623 pp | 0.00% +0.000 pp | USD1.99 -18.6% | 8 qtrs — |
| 7 | JANE STREET GROUP, LLC | 433.9K +335.6K (+341.6%) | 702.9K +470.0K (+201.8%) | 1.16% +0.897 pp | 0.00% +0.000 pp | USD1.59 +1.9% | 5 qtrs — |
| 8 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 395.8K +200.0K (+102.1%) | 641.2K +177.2K (+38.2%) | 1.06% +0.533 pp | 0.01% +0.004 pp | USD1.93 -16.1% | 6 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 305.9K +14.0K (+4.8%) | 495.8K -196.3K (-28.4%) | 0.82% +0.034 pp | 0.00% +0.000 pp | USD4.08 -60.3% | 8 qtrs — |
| 10 | PURA VIDA INVESTMENTS, LLC | 264.4K +— (+0.0%) | 428.3K -198.3K (-31.6%) | 0.71% -0.004 pp | 1.60% -2.217 pp | USD4.07 -60.2% | 8 qtrs — |
| 11 | MILLENNIUM MANAGEMENT LLC | 235.2K -75.5K (-24.3%) | 381.0K -355.3K (-48.3%) | 0.63% -0.207 pp | 0.00% 0.000 pp | USD1.70 -4.7% | 8 qtrs — |
| 12 | BLACKROCK, INC. | 224.1K +690.0 (+0.3%) | 363.1K -166.5K (-31.4%) | 0.60% -0.001 pp | 0.00% +0.000 pp | USD3.05 -46.9% | 6 qtrs — |
| 13 | TWO SIGMA ADVISERS, LP | 201.3K +150.9K (+299.4%) | 326.1K +206.7K (+173.0%) | 0.54% +0.403 pp | 0.00% +0.000 pp | USD1.81 -10.5% | 2 qtrs — |
| 14 | CITADEL ADVISORS LLC | 178.2K +178.2K (+100.0%) | 288.6K +288.6K (+100.0%) | 0.48% +0.477 pp | 0.00% +0.000 pp | USD1.62 +0.0% | 8 qtrs — |
| 15 | STATE STREET CORP | 120.4K -1.1K (-0.9%) | 195.1K -93.0K (-32.3%) | 0.32% -0.005 pp | 0.00% +0.000 pp | USD3.11 -47.9% | 7 qtrs — |
| 16 | WELLS FARGO & COMPANY/MN | 118.4K +16.4K (+16.1%) | 191.8K -49.9K (-20.7%) | 0.32% +0.043 pp | 0.00% +0.000 pp | USD4.03 -59.8% | 8 qtrs — |
| 17 | RESOLUTE ADVISORS LLC | 89.9K +— (+0.0%) | 145.7K -67.5K (-31.6%) | 0.24% -0.001 pp | 0.05% -0.007 pp | USD4.56 -64.5% | 8 qtrs — |
| 18 | MARSHALL WACE, LLP | 79.1K -12.2K (-13.3%) | 128.2K -88.2K (-40.8%) | 0.21% -0.034 pp | 0.00% 0.000 pp | USD1.48 +9.5% | 8 qtrs — |
| 19 | NORTHERN TRUST CORP | 75.2K +35.2K (+88.1%) | 121.8K +27.0K (+28.5%) | 0.20% +0.094 pp | 0.00% +0.000 pp | USD2.68 -39.6% | 8 qtrs — |
| 20 | XTX TOPCO LTD | 69.0K +53.8K (+353.4%) | 111.8K +75.7K (+209.9%) | 0.18% +0.144 pp | 0.00% +0.001 pp | USD1.79 -9.5% | 2 qtrs — |
| 21 | ACADIAN ASSET MANAGEMENT LLC | 64.9K +64.9K (+100.0%) | 105.0K +105.0K (+100.0%) | 0.17% +0.174 pp | 0.00% +0.000 pp | USD1.62 +0.0% | 1 qtrs NEW |
| 22 | RBF CAPITAL, LLC | 64.0K -6.8K (-9.5%) | 103.7K -64.0K (-38.2%) | 0.17% -0.019 pp | 0.00% -0.003 pp | USD1.48 +9.5% | 3 qtrs — |
| 23 | MORGAN STANLEY | 59.7K -181.7K (-75.3%) | 96.7K -475.3K (-83.1%) | 0.16% -0.490 pp | 0.00% +0.000 pp | USD3.20 -49.4% | 8 qtrs — |
| 24 | MAN GROUP PLC | 56.5K +3.6K (+6.8%) | 91.5K -33.8K (-27.0%) | 0.15% +0.009 pp | 0.00% 0.000 pp | USD2.32 -30.2% | 2 qtrs — |
| 25 | BBR PARTNERS, LLC | 53.4K +— (+0.0%) | 86.5K -40.1K (-31.6%) | 0.14% -0.001 pp | 0.00% -0.003 pp | USD3.61 -55.1% | 5 qtrs — |
| 26 | FORTITUDE ADVISORY GROUP L.L.C. | 38.7K +— (+0.0%) | 62.8K -29.1K (-31.6%) | 0.10% -0.001 pp | 0.03% -0.023 pp | USD3.51 -53.8% | 5 qtrs — |
| 27 | QUADRATURE CAPITAL LTD | 33.9K +33.9K (+100.0%) | 54.9K +54.9K (+100.0%) | 0.09% +0.091 pp | 0.00% +0.001 pp | USD1.62 +0.0% | 1 qtrs NEW |
| 28 | PANAGORA ASSET MANAGEMENT INC | 32.6K +32.6K (+100.0%) | 52.8K +52.8K (+100.0%) | 0.09% +0.087 pp | 0.00% +0.000 pp | USD1.62 +0.0% | 1 qtrs NEW |
| 29 | POINT72 ASSET MANAGEMENT, L.P. | 26.6K +26.6K (+100.0%) | 43.1K +43.1K (+100.0%) | 0.07% +0.071 pp | 0.00% +0.000 pp | USD1.62 +0.0% | 1 qtrs NEW |
| 30 | UBS GROUP AG | 25.1K +1.6K (+6.9%) | 40.7K -15.0K (-27.0%) | 0.07% +0.004 pp | 0.00% +0.000 pp | USD2.14 -24.3% | 8 qtrs — |
| 31 | DYNAMIC TECHNOLOGY LAB PRIVATE LTD | 23.8K -3.4K (-12.6%) | 38.0K -26.0K (-40.6%) | 0.06% -0.010 pp | 0.01% -0.002 pp | USD2.37 -31.6% | 2 qtrs — |
| 32 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 16.3K -5.2K (-24.3%) | 26.4K -24.6K (-48.2%) | 0.04% -0.014 pp | 0.00% 0.000 pp | USD2.61 -37.9% | 5 qtrs — |
| 33 | DIMENSIONAL FUND ADVISORS LP | 13.8K +13.8K (+100.0%) | 22.3K +22.3K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD1.62 +0.0% | 1 qtrs NEW |
| 34 | TWO SIGMA SECURITIES, LLC | 11.7K -489.0 (-4.0%) | 19.0K -9.9K (-34.4%) | 0.03% -0.002 pp | 0.00% -0.002 pp | USD2.37 -31.6% | 2 qtrs — |
| 35 | LPL FINANCIAL LLC | 11.3K +11.3K (+100.0%) | 18.3K +18.3K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.000 pp | USD1.62 +0.0% | 1 qtrs NEW |
| 36 | SQUAREPOINT OPS LLC | 10.6K +10.6K (+100.0%) | 17.2K +17.2K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD1.62 +0.0% | 3 qtrs — |
| 37 | HRT FINANCIAL LP | 11.1K -3.0K (-21.3%) | 17.0K -16.0K (-48.5%) | 0.03% -0.008 pp | 0.00% 0.000 pp | USD1.48 +9.5% | 3 qtrs — |
| 38 | TOWER RESEARCH CAPITAL LLC (TRC) | 9.3K +9.3K (+100.0%) | 15.1K +15.1K (+100.0%) | 0.02% +0.025 pp | 0.00% +0.000 pp | USD1.62 +0.0% | 8 qtrs — |
| 39 | RUSSELL INVESTMENTS GROUP, LTD. | 7.1K +— (+0.0%) | 11.6K -5.4K (-31.6%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD2.00 -19.0% | 5 qtrs — |
| 40 | FMR LLC | 6.8K -3.4K (-33.2%) | 11.0K -13.1K (-54.4%) | 0.02% -0.009 pp | 0.00% +0.000 pp | USD2.30 -29.6% | 6 qtrs — |
| 41 | MEEDER ASSET MANAGEMENT INC | 5.5K +— (+0.0%) | 8.9K -4.1K (-31.6%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD1.37 +18.2% | 4 qtrs — |
| 42 | US BANCORP \DE\ | 4.5K +— (+0.0%) | 7.3K -3.4K (-31.6%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD10.82 -85.0% | 8 qtrs — |
| 43 | ADVISOR GROUP HOLDINGS, INC. | 2.9K -250.0 (-8.0%) | 4.7K -1.6K (-25.5%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.73 -6.4% | 6 qtrs — |
| 44 | JPMORGAN CHASE & CO | 1.6K -61.0K (-97.4%) | 2.6K -145.7K (-98.3%) | 0.00% -0.164 pp | 0.00% +0.000 pp | USD2.40 -32.5% | 8 qtrs — |
| 45 | MASSMUTUAL TRUST CO FSB/ADV | 593.00 +— (+0.0%) | 961.00 -444.0 (-31.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.48 +9.5% | 3 qtrs — |
| 46 | NISA INVESTMENT ADVISORS, LLC | 511.00 +— (+0.0%) | 828.00 -383.0 (-31.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.26 -50.3% | 6 qtrs — |
| 47 | JONES FINANCIAL COMPANIES LLLP | 500.00 +— (+0.0%) | 810.00 -335.0 (-29.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.36 +19.1% | 4 qtrs — |
| 48 | ALLWORTH FINANCIAL LP | 500.00 +500.0 (+100.0%) | 810.00 +810.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.62 +0.0% | 1 qtrs NEW |
| 49 | BNP PARIBAS ARBITRAGE, SNC | 307.00 -14.9K (-98.0%) | 497.00 -35.5K (-98.6%) | 0.00% -0.040 pp | 0.00% +0.000 pp | USD2.41 -32.8% | 7 qtrs — |
| 50 | LARSON FINANCIAL GROUP LLC | 50.00 +— (+0.0%) | 81.00 -38.0 (-31.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.10 -68.2% | 8 qtrs — |
| 51 | BANK OF AMERICA CORP /DE/ | 42.00 -18.7K (-99.8%) | 68.00 -44.4K (-99.8%) | 0.00% -0.050 pp | 0.00% +0.000 pp | USD2.60 -37.7% | 8 qtrs — |
| 52 | OPTIVER HOLDING B.V. | 18.00 +— (+0.0%) | 29.00 -14.0 (-32.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.33 -30.5% | 2 qtrs — |
| 53 | SRS CAPITAL ADVISORS, INC. | 11.00 -19.0 (-63.3%) | 18.00 -53.0 (-74.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.36 -31.4% | 2 qtrs — |
| 54 | BARCLAYS PLC | 3.00 -8.7K (-100.0%) | 5.00 -18.9K (-100.0%) | 0.00% -0.023 pp | 0.00% +0.000 pp | USD2.33 -30.5% | 7 qtrs — |
| 55 | GREEN ALPHA ADVISORS, LLC | — -14.3K (-100.0%) | — -33.8K (-100.0%) | 0.00% -0.038 pp | 0.00% -0.033 pp | USD— | 6 qtrs SOLD |
| 56 | CITIGROUP INC | — -3.3K (-100.0%) | — -7.9K (-100.0%) | 0.00% -0.009 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 57 | ROYAL BANK OF CANADA | — -615.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 58 | RIALTO WEALTH MANAGEMENT, LLC | — -305.0 (-100.0%) | — -723.0 (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 59 | WALLEYE CAPITAL LLC | — -71.3K (-100.0%) | — -168.9K (-100.0%) | 0.00% -0.192 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 60 | MAREX GROUP PLC | — -15.0K (-100.0%) | — -34.5K (-100.0%) | 0.00% -0.040 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 61 | PRINCIPAL SECURITIES, INC. | — -544.0 (-100.0%) | — -1.3K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 62 | TANG CAPITAL MANAGEMENT LLC | — -28.0K (-100.0%) | — -66.4K (-100.0%) | 0.00% -0.075 pp | 0.00% -0.003 pp | USD— | 4 qtrs SOLD |
| 63 | PHYSICIAN WEALTH ADVISORS, INC. | — -610.0 (-100.0%) | — -1.4K (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 64 | JACOBS LEVY EQUITY MANAGEMENT, INC | — -34.2K (-100.0%) | — -81.0K (-100.0%) | 0.00% -0.092 pp | 0.00% 0.000 pp | USD— | 7 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 121.3K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 419.3K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.1K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 5.9K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 433.38 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.00M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.2K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.2K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 483.12 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 53.23 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
569.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+569,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Wein Matthew | Officer | A-Award | A | Common Stock | 11,000 | 0.00 | — | 125,549 | D | ↗ |
| 2026-04-01 | Wapnick Pamela | Officer | A-Award | A | Common Stock | 24,000 | 0.00 | — | 211,375 | D | ↗ |
| 2026-04-01 | Irish Jian | Director / Officer | A-Award | A | Common Stock | 46,000 | 0.00 | — | 379,770 | D | ↗ |
| 2026-03-05 | Wein Matthew | Officer | S-Sale | D | Common Stock | 482 | 1.60 | 771.20 | 114,549 | D | ↗ |
| 2026-03-05 | Wapnick Pamela | Officer | S-Sale | D | Common Stock | 1,581 | 1.60 | 2.5K | 187,375 | D | ↗ |
| 2026-03-05 | Irish Jian | Director / Officer | S-Sale | D | Common Stock | 1,607 | 1.60 | 2.6K | 333,770 | D | ↗ |
| 2025-12-05 | Wein Matthew | Officer | S-Sale | D | Common Stock | 199 | 1.77 | 352.61 | 115,031 | D | ↗ |
| 2025-12-05 | Wapnick Pamela | Officer | S-Sale | D | Common Stock | 1,576 | 1.77 | 2.8K | 188,956 | D | ↗ |
| 2025-12-05 | Thomas Brian C. | Director | S-Sale | D | Common Stock | 3,830 | 1.77 | 6.8K | 2,510,960 | D | ↗ |
| 2025-12-05 | Irish Jian | Director / Officer | S-Sale | D | Common Stock | 1,602 | 1.77 | 2.8K | 563,839 | D | ↗ |
| 2025-12-01 | Wein Matthew | Officer | A-Award | A | Common Stock | 96,000 | 1.60 | 153.6K | 115,230 | D | ↗ |
| 2025-12-01 | Wapnick Pamela | Officer | A-Award | A | Common Stock | 120,000 | 1.60 | 192.0K | 190,532 | D | ↗ |
| 2025-12-01 | Irish Jian | Director / Officer | A-Award | A | Common Stock | 211,000 | 1.60 | 337.6K | 565,441 | D | ↗ |
| 2025-09-05 | Wein Matthew | Officer | S-Sale | D | Common Stock | 199 | 1.81 | 360.19 | 19,230 | D | ↗ |
| 2025-09-05 | Wapnick Pamela | Officer | S-Sale | D | Common Stock | 1,576 | 1.81 | 2.9K | 70,532 | D | ↗ |
| 2025-09-05 | Thomas Brian C. | Director | S-Sale | D | Common Stock | 2,701 | 1.81 | 4.9K | 2,514,790 | D | ↗ |
| 2025-09-05 | Irish Jian | Director / Officer | S-Sale | D | Common Stock | 1,602 | 1.81 | 2.9K | 316,941 | D | ↗ |
| 2025-09-02 | Reid Laurence | Director | A-Award | A | Stock Option (Right to Buy) | 42,000 | 1.82 | 76.4K | 42,000 | D | ↗ |
| 2025-08-11 | Reid Laurence | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-10 | Eckhardt Juergen | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 1.57 | 33.0K | 21,000 | D | ↗ |
| 2025-06-10 | Dere Willard H | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 1.57 | 33.0K | 21,000 | D | ↗ |
| 2025-06-10 | BJERKHOLT ERIC | Director | A-Award | A | Stock Option (Right to Buy) | 8,572 | 1.57 | 13.5K | 8,572 | D | ↗ |
| 2025-06-06 | Wein Matthew | Officer | S-Sale | D | Common Stock | 199 | 1.75 | 348.25 | 16,693 | D | ↗ |
| 2025-06-06 | Wapnick Pamela | Officer | S-Sale | D | Common Stock | 1,576 | 1.75 | 2.8K | 72,108 | D | ↗ |
| 2025-06-06 | Thomas Brian C. | Director / Officer | S-Sale | D | Common Stock | 10,785 | 1.75 | 18.9K | 2,517,491 | D | ↗ |
| 2025-06-06 | Noonberg Sarah B. | Officer | S-Sale | D | Common Stock | 5,239 | 1.75 | 9.2K | 109,135 | D | ↗ |
| 2025-06-06 | Irish Jian | Director / Officer | S-Sale | D | Common Stock | 6,390 | 1.75 | 11.2K | 315,543 | D | ↗ |
| 2025-04-01 | Wein Matthew | Officer | A-Award | A | Stock Option (Right to Buy) | 22,725 | 1.32 | 30.0K | 22,725 | D | ↗ |
| 2025-04-01 | Wapnick Pamela | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 73,684 | D | ↗ |
| 2025-04-01 | Thomas Brian C. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 196,000 | 1.32 | 258.7K | 196,000 | D | ↗ |
| 2025-04-01 | Noonberg Sarah B. | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 114,374 | D | ↗ |
| 2025-04-01 | Irish Jian | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 140,000 | 1.32 | 184.8K | 140,000 | D | ↗ |
| 2024-02-08 | Novo Holdings A/S | 10% Owner | — | D | SERIES B PREFERRED STOCK | 147,415 | 0.00 | — | 0 | — | ↗ |
| 2024-02-08 | Noonberg Sarah B. | Officer | — | D | Common Stock | 0 | 0.00 | — | 42,611 | — | ↗ |
| 2024-02-08 | Borges Luis | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-4.8K
Shares Outstanding
37.62M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jian Irish, Ph.D., M.B.A. President and Chief Executive Officer | 570.7K | — | 428.0K | 402.8K | 252.6K | 13.9K | 1.67M | 49.81% | ↗ |
| 2 | 2025 | Brian C. Thomas, Ph.D. Former Chief Executive Officer | 563.0K | — | 42.2K | 191.1K | — | 599.7K | 1.40M | 16.71% | ↗ |
| 3 | 2025 | Pamela Wapnick, M.B.A. Chief Financial Officer | 464.0K | — | 210.5K | 81.9K | 161.1K | 17.5K | 935.0K | 31.27% | ↗ |
| 4 | 2025 | Matthew L. Wein, J.D. General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary | 407.2K | — | 163.4K | 43.5K | 124.9K | 17.5K | 756.4K | 27.35% | ↗ |
| 5 | 2024 | Brian C. Thomas, Ph.D. Former Chief Executive Officer | 628.3K | — | 1.29M | 3.86M | 265.2K | 19.8K | 6.06M | 84.93% | ↗ |
| 6 | 2024 | Brian C. Thomas, Ph.D. Chief Executive Officer | 628.3K | — | 1.29M | 3.86M | 265.2K | 19.8K | 6.06M | 84.93% | ↗ |
| 7 | 2024 | Jian Irish, Ph.D., M.B.A. President and Chief Executive Officer | 536.3K | — | 762.5K | 2.29M | 187.0K | 11.3K | 3.78M | 80.58% | ↗ |
| 8 | 2024 | Jian Irish, Ph.D., M.B.A. President and Chief Operating Officer | 536.3K | — | 762.5K | 2.29M | 187.0K | 11.3K | 3.78M | 80.58% | ↗ |
| 9 | 2024 | Pamela Wapnick, M.B.A. Chief Financial Officer | 445.0K | — | 750.0K | 2.25M | 122.4K | 14.4K | 3.58M | 83.75% | ↗ |
| 10 | 2023 | Brian C. Thomas, Ph.D. Chief Executive Officer | 516.7K | 20.0K | 6.97M | — | 288.6K | 34.1K | 7.83M | 89.02% | ↗ |
| 11 | 2023 | Jian Irish, Ph.D., M.B.A. President and Chief Operating Officer | 465.0K | 15.0K | 1.78M | — | 231.4K | 18.4K | 2.51M | 70.96% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brian Charles Thomas | Co-Founder & Director | 1M | — |
| Jian Irish | CEO, President & Director | 837.2K | — |
| Pamela Wapnick | Chief Financial Officer | 642.6K | female |
| Matthew L. Wein | General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary | 549.5K | male |
| Katalin Kauser | Senior Vice President of Translational Biology | — | female |
| Joseph Knowles | Co-Founder & Member of Scientific Advisory Board | — | — |
| Alan Brooks | Senior Vice President of Research | — | — |
| Mark Leonard | Senior Vice President of Technical Development & Operations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MGX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
